A new investigational drug, from Eisai and Biogen, has shown promising results for slowing progression of cognitive decline during Phase 3 clinical trial. 

1,795 individuals diagnosed with early Alzheimer's disease were enrolled in the study and the drug slowed disease progression by 27% compared to the placebo. 

lecanemab is a monoclonal antibody which targets amyloid build-up in the brain, which is then cleared by the immune system. It is believed that memory loss and confusion associated with Alzheimer's is caused by a build-up of amyloid in the brain which can contribute to brain cells being killed.

Alzheimer's is a degenerative brain disease, which sadly many of us will have experienced the effects of. Progress by the Pharma sector in slowing or even one day curing this awful disease is a wonderful thing!